MediPharm Labs Breaks Free From Royalty Agreement, What It Means & What's Next
MediPharm Labs Breaks Free From Royalty Agreement, What It Means & What's Next
MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) has executed a supplementary agreement to its asset purchase agreement with 1193269 B.C. Ltd., operating as Shelter Cannabis for the Shelter Cannabis Brands IP portfolio, ending any ongoing royalty payments after August 31, 2023.
醫療藥業實驗室公司(多倫多證券交易所：實驗室)(場外交易：MEDIF)(法蘭克福證券交易所：MLZ)與1193269西元前有限公司簽署了資產購買協定的補充協定，作為庇護所大麻品牌IP組合的庇護所大麻運營，在2023年8月31日之後停止任何持續的特許權使用費支付。
Under the existing asset purchase agreement, executed in March 2022, MediPharm Labs purchased the IP of Shelter Cannabis Brands. This IP has been focused in the market on Wildlife Cannabis domestic dry flower and pre-roll products that are manufactured and distributed via the MediPharm sites.
根據2022年3月簽署的現有資產購買協定，MediPharm Labs購買了庇護所大麻品牌的知識產權。這一知識產權一直集中在市場上的野生動物大麻，家庭乾花和預捲產品，這些產品是通過MediPharm網站製造和分銷的。
Why It Matters
為什麼這很重要
The supplementary agreement allows for an improvement in this product line's gross margin, providing flexibility for the Toronto-based company to further invest in the brand to drive sales as it continues on the path to profitability.
補充協定允許這條產品線的毛利率有所提高，為這家總部位於多倫多的公司提供靈活性，以進一步投資於該品牌，以推動銷售，使其繼續走上盈利之路。
What's Next
接下來是什麼？
MediPharm said on Wednesday that it will continue to review every product category and selling channel to optimize margins and streamline business operations to achieve its profitability goal.
MediPharm週三表示，將繼續審查每個產品類別和銷售渠道，以優化利潤率和精簡業務運營，以實現盈利目標。
MediPharm's Research Efforts
醫療藥業的研究努力
Meanwhile, MediPharm is no stranger to innovation either.
與此同時，醫藥公司對創新也並不陌生。
Its Harvest Medicine subsidiary recently conducted a study that revealed that medical cannabis may effectively manage fibromyalgia and associated symptoms of depression and anxiety.
其子公司嘉實醫藥最近進行的一項研究顯示，醫用大麻可能有效地控制纖維肌痛以及相關的抑鬱和焦慮症狀。
The research showed that 75% of patients who mainly used CBD oil saw a decrease in their self-reported illness severity, which may include chronic pain, insomnia, and fatigue.
研究表明，在主要使用CBD油的患者中，75%的患者自我報告的疾病嚴重程度有所下降，可能包括慢性疼痛、失眠和疲勞。
To learn more about cannabis innovation, come join us at the upcoming Benzinga marijuana event in Chicago.
要了解更多關於大麻創新的資訊，請加入我們即將舉行的芝加哥的Benzinga大麻活動。
The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.
Benzinga Cannabis Capital Conference是達成交易的地方，將於今年9月27日至28日返回芝加哥舉行第17屆。在價格上漲之前今天就買到票，並在大麻投資和品牌推廣的中心獲得一席之地。
MEDIF Price Action
MEDIF價格行動
MediPharm's shares traded 1.35% higher at $81.99 per share during the pre-market session on Wednesday morning.
MediPharm股價上漲1.35%，至每股81.99美元。在週三上午的開盤前交易中。
Related News
相關新聞
- Two Pot Companies Continue To Focus On Cannabinoid-Based Self-Emulsifying Drug Delivery Systems
- MediPharm Delivers Cannabis Clinical Trial Material To US Research Partner And Provides Update On FDA Status
- Cannabinoid-Focused Pharma Stock Slides On Q2 Earnings Report, Here Are The Details
- 兩家大麻公司繼續專注於基於大麻素的自乳化藥物輸送系統
- MediPharm向美國研究合作夥伴提供大麻臨床試驗材料並提供FDA最新情況
- 專注於大麻類藥物的製藥股第二季度收益報告幻燈片，以下是詳細資訊
Photo: Courtesy of Tim Foster on Unsplash
圖片：由蒂姆·福斯特在Unspash上提供